AltPep

AltPep is a biotechnology startup established in 2019, headquartered in the United States. The company specializes in developing early disease-modifying treatments and detection tools for amyloid diseases, focusing on toxic soluble oligomers, a key molecular trigger. This novel approach is backed by decades of research from the Daggett Research Group and is predicated on the discovery of the alpha-sheet protein structure.

AltPep's leading program targets the early detection and neutralization of toxic oligomers in Alzheimer’s Disease before symptoms manifest, positioning the company at the forefront of neurodegenerative disease research.

In June 2023, AltPep secured a significant $52.90M Series B investment from a consortium of prominent investors, including Partners Investment, Alexandria Venture Investments, Eli Lilly, Section 32, Senator Investment Group, and Matrix Capital Management. This investment underscores strong confidence in AltPep's pioneering technology and capacity to impact a critical industry space.